Skip to main content

Table 2 Mean values (±SD) of clinical outcomes measure after RAGT ± VR. Within- and between-group comparisons, with confidence interval (95%) (CI), are reported. Not reported data are non-significant

From: The role of virtual reality in improving motor performance as revealed by EEG: a randomized clinical trial

parameter

Group

PRE

POST

Within-group

Between-group

CI (95%)

RMI

RAGT + VR

8 ± 1

14 ± 1

<0.001

0.001

1.2 to 7.6

RAGT-VR

7 ± 1

9 ± 1

0.01

POMA

RAGT + VR

17 ± 3

23 ± 3

0.001

0.01

1.2 to 7.6

RAGT-VR

12 ± 4

15 ± 4

 

MAS

RAGT + VR

2 ± 0.5

2 ± 0.5

   

RAGT-VR

2 ± 0.5

2 ± 0.5

 

HRS

RAGT + VR

11 ± 3

7 ± 3

0.01

  

RAGT-VR

13 ± 3

10 ± 3

0.02

VAS

RAGT + VR

6 ± 1

8 ± 1

<0.001

0.01

1.3 to 15.3

RAGT-VR

5 ± 1

6 ± 1

 

drowsiness episodes

RAGT + VR

5 ± 1

2 ± 1

<0.001

0.009

1 to 6.9

RAGT-VR

5 ± 1

5 ± 1

 

Hip force

RAGT + VR

36 ± 7

42 ± 3

0.01

0.02

−6.2 to −3.8

RAGT-VR

34 ± 6

38 ± 10

 

Knee force

RAGT + VR

31 ± 8

47 ± 6

<0.001

0.02

 

RAGT-VR

30 ± 7

36 ± 3

0.04

  1. Legend: RMI Rivermead Mobility Index; POMA Tinetti Performance Oriented Mobility Assessment; MAS Modified Ashwort Scale; HRS Hamilton Rating Scale for depression; VAS visual analogic scale